港股異動 | 兆科眼科大升19% FDA已接納審理公司夥伴Vyluma的新藥申請

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

港股異動 | 兆科眼科大升19% FDA已接納審理公司夥伴Vyluma的新藥申請

格隆匯 06-07 15:25

格隆匯6月7日丨兆科眼科(6622.HK)升幅擴大至19%，4日累計升幅高達40%走出V型走勢，現報3.41港元，總市值18.6億港元。公司的夥伴Vyluma Inc.(Vyluma)已宣佈美國食品藥品監督管理局(FDA)已接納審理Vyluma的主要複方NVK002(低劑量阿托品0.01%)作為兒童近視的潛在療法的新藥申請。

兆科眼科-B(06622.HK)

Relevant Stocks

兆科眼科-B(06622.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

港股異動 | 兆科眼科大升19% FDA已接納審理公司夥伴Vyluma的新藥申請

Services

About Us

Agreement Statement